At present, traditional circulating tumor markers in the setting of clinical laboratories such as CEA and CA19-9 have low specificity and sensitivity (Sekiguchi and Matsuda 2020), which limited their clinical application. The gene discussed is CEACAM5; the disease is neoplasm.